CorMedix Inc. (CRMD)
NASDAQ: CRMD · Real-Time Price · USD
11.13
-0.49 (-4.22%)
At close: Oct 31, 2025, 4:00 PM EDT
11.18
+0.05 (0.45%)
After-hours: Oct 31, 2025, 7:49 PM EDT
CorMedix Employees
As of December 31, 2024, CorMedix had 65 total employees, including 64 full-time and 1 part-time employees. The number of employees decreased by 18 or -21.69% compared to the previous year.
Employees
65
Change (1Y)
-18
Growth (1Y)
-21.69%
Revenue / Employee
$1,868,992
Profits / Employee
$787,069
Market Cap
872.03M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 65 | -18 | -21.69% |
| Dec 31, 2023 | 83 | 42 | 102.44% |
| Dec 31, 2022 | 41 | 11 | 36.67% |
| Dec 31, 2021 | 30 | -5 | -14.29% |
| Dec 31, 2020 | 35 | 5 | 16.67% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CRMD News
- 18 hours ago - CorMedix Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 12, 2025 - GlobeNewsWire
- 8 days ago - CorMedix: Strong Buy After Strong Developments And A Strategy Before Earnings - Seeking Alpha
- 8 days ago - CorMedix Inc. Receives Innovative Technology Designation From Vizient for DefenCath - GlobeNewsWire
- 9 days ago - Halper Sadeh LLC Encourages CorMedix Inc. Shareholders to Contact the Firm to Discuss Their Rights - Business Wire
- 11 days ago - CRMD, RANI, CELC, RAPT: four biotech stocks flying high today and why - Invezz
- 11 days ago - CorMedix Inc. Announces Preliminary Third Quarter 2025 Results and Raises 2025 Net Revenue Guidance - GlobeNewsWire
- 4 weeks ago - CorMedix Announces Completion of Enrollment in Phase III ReSPECT Clinical Trial for REZZAYO - GlobeNewsWire
- 5 weeks ago - CorMedix: Strong Adoption Curve And Policy Environment - Seeking Alpha